Effects of Epicatechin on Functional Capacity, Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 40 - 60 |
| Updated: | 7/11/2015 |
| Start Date: | January 2014 |
| End Date: | January 2016 |
| Contact: | Minal V Patel |
| Email: | chocolatestudy2@gmail.com |
| Phone: | 858-657-5354 |
The major goal of this proposal is to characterize the ability of epicatechin which a
component of dark chocolate to improve the
1. structural and functional features of skeletal muscle (SkM)
2. exercise capacity (as assessed by VO2 max)
3. parameters of diastolic heart function (as assessed by echocardiography)
We propose that a 3 month treatment with epicatechin (through CocoaVia® capsules) will lead
to a significant improvement in exercise capacity and diastolic function.
component of dark chocolate to improve the
1. structural and functional features of skeletal muscle (SkM)
2. exercise capacity (as assessed by VO2 max)
3. parameters of diastolic heart function (as assessed by echocardiography)
We propose that a 3 month treatment with epicatechin (through CocoaVia® capsules) will lead
to a significant improvement in exercise capacity and diastolic function.
Patient Inclusion/Exclusion Criteria:
1. New York Heart Association Class II/III HF with preserved ejection fraction (EF) of
>50%.
2. Nonsmokers
3. Subject not taking Coumadin, Xarelto, Prasugrel or Pradaxa. Patients on Plavix for drug
eluting stent will not be excluded.
4. Ages between 40-65. We will exclude any women of child bearing potential
1. New York Heart Association Class II/III HF with preserved ejection fraction (EF) of
>50%.
2. Nonsmokers
3. Subject not taking Coumadin, Xarelto, Prasugrel or Pradaxa. Patients on Plavix for drug
eluting stent will not be excluded.
4. Ages between 40-65. We will exclude any women of child bearing potential
Inclusion Criteria:
- Medically Diagnosed Heart Failure with Ejection Fraction of >55%
- BMI 27-32
- No Significant HbA1C fluctuations in past 6 months
Exclusion Criteria:
- Smoking or quit smoking less than 1 year prior to enrollment
- Substance Abuse
- Taking Coudmadin or Pradaxa
We found this trial at
1
site
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
Click here to add this to my saved trials
